リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「An attenuated vaccinia vaccine encoding the severe acute respiratory syndrome coronavirus-2 spike protein elicits broad and durable immune responses, and protects cynomolgus macaques and human angiotensin-converting enzyme 2 transgenic mice from severe acute respiratory syndrome coronavirus-2 and its variants」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

An attenuated vaccinia vaccine encoding the severe acute respiratory syndrome coronavirus-2 spike protein elicits broad and durable immune responses, and protects cynomolgus macaques and human angiotensin-converting enzyme 2 transgenic mice from severe acute respiratory syndrome coronavirus-2 and its variants

ISHIGAKI Hirohito 90432301 YASUI Fumihiko 40399473 0000-0002-3757-2569 NAKAYAMA Misako 00510306 ENDO Akinori 50796844 YAMAMOTO Naoki 10547780 YAMAJI Kenzaburo 40508628 NGUYEN Cong Thanh 0000-0002-5973-6210 KITAGAWA Yoshinori 00444448 SANADA Takahiro 60721272 0000-0002-6362-7762 HONDA Tomoko MUNAKATA Tsubasa HIGA Masahiko TOYAMA Sakiko KONO Risa TAKAGI Asako MATSUMOTO Yusuke 00735912 KOSEKI Aya HAYASHI Kaori 70569251 SHIOHARA Masanori ISHII Koji 40280763 0000-0003-3812-0094 SAEKI Yasushi 80462779 ITOH Yasushi 90324566 KOHARA Michinori 10250218 滋賀医科大学

2022.11.18

概要

As long as the coronavirus disease-2019 (COVID-19) pandemic continues, new variants of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) with altered antigenicity will emerge. The development of vaccines that elicit robust, broad, and durable protection against SARS-CoV-2 variants is urgently required. We have developed a vaccine consisting of the attenuated vaccinia virus Dairen-I (DIs) strain platform carrying the SARS-CoV-2 S gene (rDIs-S). rDIs-S induced neutralizing antibody and T-lymphocyte responses in cynomolgus macaques and human angiotensin-converting enzyme 2 (hACE2) transgenic mice, and the mouse model showed broad protection against SARS-CoV-2 isolates ranging from the early-pandemic strain (WK-521) to the recent Omicron BA.1 variant (TY38-873). Using a tandem mass tag (TMT)-based quantitative proteomic analysis of lung homogenates from hACE2 transgenic mice, we found that, among mice subjected to challenge infection with WK-521, vaccination with rDIs-S prevented protein expression related to the severe pathogenic effects of SARS-CoV-2 infection (tissue destruction, inflammation, coagulation, fibrosis, and angiogenesis) and restored protein expression related to immune responses (antigen presentation and cellular response to stress). Furthermore, long-term studies in mice showed that vaccination with rDIs-S maintains S protein-specific antibody titers for at least 6 months after a first vaccination. Thus, rDIs-S appears to provide broad and durable protective immunity against SARS-CoV-2, including current variants such as Omicron BA.1 and possibly future variants.

論文の公開元へ

この論文で使われている画像

関連論文

関連論文をもっと見る

参考文献

Altenburg, A. F., Kreijtz, J., de Vries, R., Song, F., Fux, R., Rimmelzwaan, G., et al. (2014). Modified vaccinia virus Ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. Viruses 6, 2735–2761. doi: 10.3390/v6072735

Chiuppesi, F., Salazar, M. A., Contreras, H., Nguyen, V. H., Martinez, J., Park, Y., et al. (2020). Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform. Nat. Commun. 11:6121. doi: 10.1038/s41467- 020-19819-1

Cines, D. B., and Bussel, J. B. (2021). SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. N. Engl. J. Med. 384, 2254–2256. doi: 10.1056/ NEJMe2106315

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses (2020). The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 5, 536–544. doi: 10.1038/s41564-020-0695-z

Dai, L., and Gao, G. F. (2021). Viral targets for vaccines against COVID-19. Nat. Rev. Immunol. 21, 73–82. doi: 10.1038/s41577-020-00480-0

Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., et al. (2020). Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single- blind, randomised controlled trial. Lancet 396, 467–478. doi: 10.1016/ S0140-6736(20)31604-4

García-Arriaza, J., Garaigorta, U., Pérez, P., Lázaro-Frías, A., Zamora, C., Gastaminza, P., et al. (2021). COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T-and B-cell immune responses and full efficacy in mice. J. Virol. 95, e02260–e02320. doi: 10.1128/JVI.02260-20

Goedhart, J., and Luijsterburg, M. S. (2020). Volca NoseR is a web app for creating, exploring, labeling and sharing volcano plots. Sci. Rep. 10:20560. doi: 10.1038/ s41598-020-76603-3

Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., et al. (2020). Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cells 181, 1489–1501.e15. doi: 10.1016/j.cell.2020.05.015

Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., et al. (2020). SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cells 181, 271–280.e8. doi: 10.1016/j.cell.2020.02.052

Ishigaki, H., Nakayama, M., Kitagawa, Y., Nguyen, C. T., Hayashi, K., Shiohara, M., et al. (2021). Neutralizing antibody-dependent and-independent immune responses against SARS-CoV-2 in cynomolgus macaques. Virology 554, 97–105. doi: 10.1016/j. virol.2020.12.013

Ishii, K., Hasegawa, H., Nagata, N., Mizutani, T., Morikawa, S., Tashiro, M., et al. (2006). Highly attenuated vaccinia virus DIs as a potential SARS vaccine. Adv. Exp. Med. Biol. 581, 593–596. doi: 10.1007/978-0-387-33012-9_107

Ishii, K., Ueda, Y., Matsuo, K., Matsuura, Y., Kitamura, T., Kato, K., et al. (2002). Structural analysis of vaccinia virus DIs strain: application as a new replication- deficient viral vector. Virology 302, 433–444. doi: 10.1006/viro.2002.1622

Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., et al. (2020). An mRNA vaccine against SARS-CoV-2-preliminary report. N. Engl. J. Med. 383, 1920–1931. doi: 10.1056/NEJMoa2022483

Jara, A., Undurraga, E. A., González, C., Paredes, F., Fontecilla, T., Jara, G., et al. (2021). Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N. Engl. J. Med. 385, 875–884. doi: 10.1056/NEJMoa2107715

Ju, B., Zhang, Q., Ge, J., Wang, R., Sun, J., Ge, X., et al. (2020). Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature 584, 115–119. doi: 10.1038/ s41586-020-2380-z

Kato, H., Miyakawa, K., Ohtake, N., Yamaoka, Y., Yajima, S., Yamazaki, E., et al. (2022). Vaccine-induced humoral response against SARS-CoV-2 dramatically declined but cellular immunity possibly remained at 6 months post BNT162b2 vaccination. Vaccine 40, 2652–2655. doi: 10.1016/j.vaccine.2022.03.057

Kitabatake, M., Inoue, S., Yasui, F., Yokochi, S., Arai, M., Morita, K., et al. (2007). SARS-CoV spike protein-expressing recombinant vaccinia virus efficiently induces neutralizing antibodies in rabbits pre-immunized with vaccinia virus. Vaccine 25, 630–637. doi: 10.1016/j.vaccine.2006.08.039

Kollias, A., Kyriakoulis, K. G., Dimakakos, E., Poulakou, G., Stergiou, G. S., and Syrigos, K. (2020). Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action. Br. J. Haematol. 189, 846–847. doi: 10.1111/bjh.16727

Levin, E. G., Lustig, Y., Cohen, C., Fluss, R., Indenbaum, V., Amit, S., et al. (2021). Waning immune Humoral response to BNT162b2 Covid-19 vaccine over 6 months. N. Engl. J. Med. 385:e84. doi: 10.1056/NEJMoa2114583

Liu, R., Americo, J. L., Cotter, C. A., Earl, P. L., Erez, N., Peng, C., et al. (2021). One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower respiratory tract infection. Proc. Natl. Acad. Sci. U. S. A. 118:e2026785118. doi: 10.1073/pnas.2026785118

Logunov, D. Y., Dolzhikova, I. V., Zubkova, O. V., Tukhvatulin, A. I., Shcheblyakov, D. V., Dzharullaeva, A. S., et al. (2020). Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet 396, 887–897. doi: 10.1016/S0140-6736(20)31866-3

Matsumoto, Y., Yasui, F., Endo, A., Sanada, T., Munakata, T., Takagi, A., et al. (2022). Early circulating strain of SARS-CoV-2 causes severe pneumonia distict from that caused by variants of concern. Research Square [Preprint]. doi: 10.21203/rs.3.rs-1267705/v1

Matsuyama, S., Nao, N., Shirato, K., Kawase, M., Saito, S., Takayama, I., et al. (2020). Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc. Natl. Acad. Sci. U. S. A. 117, 7001–7003. doi: 10.1073/pnas.2002589117

Mercado, N. B., Zahn, R., Wegmann, F., Loos, C., Chandrashekar, A., Yu, J., et al. (2020). Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature 586, 583–588. doi: 10.1038/s41586-020-2607-z

Mortensen, R. M., and Kingston, R. E. (2009). Selection of transfected mammalian cells. Curr. Protoc. Mol. Biol. 9:86. doi: 10.1002/0471142727.mb0905s86

Nie, X., Qian, L., Sun, R., Huang, B., Dong, X., Xiao, Q., et al. (2021). Multi-organ proteomic landscape of COVID-19 autopsies. Cells 184, 775–791.e14. doi: 10.1016/j. cell.2021.01.004

Ogiwara, H., Yasui, F., Munekata, K., Takagi-Kamiya, A., Munakata, T., Nomura, N., et al. (2014). Histopathological evaluation of the diversity of cells susceptible to H5N1 virulent avian influenza virus. Am. J. Pathol. 184, 171–183. doi: 10.1016/j.ajpath.2013.10.004

Pan, Y., Liu, L., Tian, T., Zhao, J., Park, C. O., Lo@us, S. Y., et al. (2021). Epicutaneous immunization with modified vaccinia Ankara viral vectors generates superior T cell immunity against a respiratory viral challenge. NPJ Vaccines 6:1. doi: 10.1038/s41541-020-00265-5

Peng, Y., Mentzer, A. J., Liu, G., Yao, X., Yin, Z., Dong, D., et al. (2020). Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat. Immunol. 21, 1336–1345. doi: 10.1038/s41590-020-0782-6

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., et al. (2020). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615. doi: 10.1056/NEJMoa2034577

Routhu, N. K., Cheedarla, N., Gangadhara, S., Bollimpelli, V. S., Boddapati, A. K., Shiferaw, A., et al. (2021). A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs. Immunity 54, 542–556.e9. doi: 10.1016/j.immuni.2021.02.001

Sadoff, J., Gray, G., Vandebosch, A., Cárdenas, V., Shukarev, G., Grinsztejn, B., et al. (2021). Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N. Engl. J. Med. 384, 2187–2201. doi: 10.1056/NEJMoa2101544

Silva-Cayetano, A., Foster, W. S., Innocentin, S., Belij-Rammerstorfer, S., Spencer, A. J., Burton, O. T., et al. (2021). A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice. Medicine 2, 243–262.e8. doi: 10.1016/j.medj.2020.12.006

Tagaya, I., Kitamura, T., and Sano, Y. (1961). A new mutant of dermovaccinia virus. Nature 192, 381–382. doi: 10.1038/192381a0

Tanriover, M. D., Doğanay, H. L., Akova, M., Güner, H. R., Azap, A., Akhan, S., et al. (2021). Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet 398, 213–222. doi: 10.1016/S0140-6736(21)01429-X

Tscherne, A., Schwarz, J. H., Rohde, C., Kupke, A., Kalodimou, G., Limpinsel, L., et al. (2021). Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination. Proc. Natl. Acad. Sci. U. S. A. 118:e2026207118. doi: 10.1073/pnas.2026207118

Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C. L., Abiona, O., et al. (2020). Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260–1263. doi: 10.1126/science.abb2507

Yasui, F., Itoh, Y., Ikejiri, A., Kitabatake, M., Sakaguchi, N., Munekata, K., et al. (2016). Sensitization with vaccinia virus encoding H5N1 hemagglutinin restores immune potential against H5N1 influenza virus. Sci. Rep. 6:37915. doi: 10.1038/ srep37915

Zhou, P., Yang, X. L., Wang, X. G., Hu, B., Zhang, L., Zhang, W., et al. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273. doi: 10.1038/s41586-020-2012-7

Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A. H., Tanaseichuk, O., et al. (2019). Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun. 10:1523. doi: 10.1038/s41467-019-09234-6

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る